Nicholas Piramal has reported an above average topline growth of 17% (vis–a–vis the overall domestic pharmaceutical growth of 10.8%) primarily due to introduction of new products such as Rejoint as well as Omnatax and Haemaccel which were acquired from Hoechst Marrion last year. Of the 19% growth in formulation sales in the second quarter almost 9% was from the acquired brands. Vitamin A which contributed around 13% to the company's turnover showed a growth of 10%. Besides, the company has been a beneficiary of the price hike that would yield Rs 40 m in the current year.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
Earnings Per Share
The company's R & D is focussing on five New Chemical Entities of which two are in the cardiovascular segment, one addresses the anti–cancer segment, one addresses the anti–diabetic segment and one for the fungal segment. These are expected to take around one and a half years more before the company reaches the stage of clinical trials.
However, the company's plans to float a US $ 70m –100m ADR issue have been deferred. The resources were to be used for upgrading its research for Mulund and setting up a a clinical research facility. A part of the proceeds was to be used to fund acquisitions both domestic and overseas. The managment was of the view that the company would raise resources via borrowings and tighten working capital management.
The stock quotes a price of Rs 312, which implies an earnings multiple of 14.7 times FY01 earnings.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407